Around the world, almost 10 million people are infected with the disease – mostly in Central and South America and parts of the USA. Tourism and immigration, however, are also bringing the disease to Europe.
Microfluidic cartridge with integrated reagents and pumps, developed as part of the Fraunhofer ivD platform
Photo: Fraunhofer ENAS / Andreas Morschhauser
One bite can have fatal consequences
The disease is passed on by blood-sucking bugs of the Reduviidae family, whose bite contaminates the wound and ultimately transmits the infection. The acute phase of the illness starts after four weeks and can last up to another four weeks. 30 – 40% of infected people have symptoms such as local redness, swelling around the wound, fever, and nausea. Treatment is only effective if started in this phase of the illness.
After a symptomless stage, which can last for years, the chronic, acute and frequently fatal phase of the illness begins. In 20% of cases, the heart and alimentary organs expand until they fail.
Scientists are concerned because there is still no inoculation. Current methods of treatment not only have serious side effects, they are also unaffordable for many patients.
Effective test offers a chance for a treatment
Under the direction of Fraunhofer ENAS, a European-Brazilian consortium is developing an on-site test, similar to a laboratory analysis, that can detect the infection quickly and reliably.
Scientists from eight European and five Brazilian research institutions and companies are developing a compact, low-cost detection system that can find the pathogen at any location. Three partners of the Heterogeneous Technology Alliance HTA are among them: CEA Leti from France, the Fraunhofer Institute for Electronic Nanosystems ENAS from Germany, and Teknologian tutkimuskeskus VTT from Finland.
The pathogen is detected in, say, a blood sample by searching for both its own DNA and the immune response from the patient’s body. The test allows highly specific diagnosis in all stages of the infection. Including sample pretreatment, the entire test system is the size of a cellular phone.
The researchers are receiving funding from the European Union and the National Council for Scientific and Technological Development in Brazil. The project “PodiTrodi – Technology platform for Point-of-care diagnostics for tropical diseases“ (EU-FP7-287770) started in September 2011 and was planned to run for two and a half years. The system will later be used as a technology platform for other tropical diseases.
Further information is available at http://www.poditrodi.org.European consortium:
• Universidade Federal do Paraná
Molecular Force Sensors
20.09.2017 | Max-Planck-Institut für Biochemie
Foster tadpoles trigger parental instinct in poison frogs
20.09.2017 | Veterinärmedizinische Universität Wien
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
20.09.2017 | Life Sciences
20.09.2017 | Power and Electrical Engineering
20.09.2017 | Physics and Astronomy